Senores Pharmaceuticals Q4 FY26: Margin Expansion, Cash Flow Recovery, and a Bigger Regulated-Market Pipeline

FY26 total income was INR 664.0 crore, up 61.8% year-on-year (from INR 410.3 crore).

FY26 EBITDA was INR 199.6 crore (EBITDA margin 30.1%) and PAT was INR 121.5 crore (PAT margin 18.3%).

FY26 segment revenues were: Regulated Markets INR 427.4 crore, Emerging Markets INR 145.0 crore, Branded Generics INR 40.0 crore, and Others Operating Income including API sales INR 51.6 crore.

As of March 2026, the company reported 51 approved ANDAs covering 151 strengths, with 21 commercialized ANDAs (46 strengths) and 30 approved ANDAs yet to be launched.

Management indicated FY27 revenue growth of approximately 30% to 40% and PAT growth of about 50% to 60%, with blended EBITDA margin guidance of 29% to 31%.

Management guided that Apnar facility revenue for FY27 is expected to be around INR 80 crore to INR 100 crore, with ramp-up commencing from April 2026 shipments.